Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale [0.03%]
难治性抑郁的辅剂5-羟色胺慢释治疗：临床与前临床依据
Jacob P R Jacobsen,Andrew D Krystal,K Ranga R Krishnan et al.
Jacob P R Jacobsen et al.
Serotonin transporter (SERT) inhibitors treat depression by elevating brain extracellular 5-hydroxytryptamine (5-HTExt). However, only one-third of patients respond adequately. Treatment-resistant depression (TRD) is a major unmet need. Int...
Allostatic Mechanisms of Opioid Tolerance Beyond Desensitization and Downregulation [0.03%]
阿片类药物耐受性的非稳态机制超出脱敏和下调的作用
Catherine M Cahill,Wendy Walwyn,Anna M W Taylor et al.
Catherine M Cahill et al.
Mechanisms of opioid tolerance have focused on adaptive modifications within cells containing opioid receptors, defined here as cellular allostasis, emphasizing regulation of the opioid receptor signalosome. We review additional regulatory ...
Amit Mogha,Mitchell D&#x;Rozario,Kelly R Monk
Amit Mogha
The G protein-coupled receptor (GPCR) superfamily represents the largest class of functionally selective drug targets for disease modulation and therapy. GPCRs have been studied in great detail in central nervous system (CNS) neurons, but t...
Invalidation of Atorvastatin Patent Highlights Complex Chinese Patent Law [0.03%]
阿托伐他汀专利失效凸显复杂的中国专利法环境
Feng-Chi Chen,Kuo-Liang Yeh
Feng-Chi Chen
Pfizer's atorvastatin (Lipitor) is a blockbuster drug for the treatment of cardiovascular diseases. In China, a critical polymorph patent of this drug has been recently invalidated by the Supreme People's Court for insufficiency of disclosu...
Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors [0.03%]
膜转运蛋白介导的小分子酪氨酸激酶抑制剂耐药性的影响
Claudia Neul,Elke Schaeffeler,Alex Sparreboom et al.
Claudia Neul et al.
Small-molecule inhibitors of tyrosine kinases (TKIs) are the mainstay of treatment for many malignancies and represent novel treatment options for other diseases such as idiopathic pulmonary fibrosis. Twenty-five TKIs are currently FDA-appr...
Epoxyeicosatrienoic Acid as Therapy for Diabetic and Ischemic Cardiomyopathy [0.03%]
epoxyeicosatrienoic acid在糖尿病和缺血性心肌病治疗中的应用
Mikhail Romashko,Joseph Schragenheim,Nader G Abraham et al.
Mikhail Romashko et al.
Cardiovascular disease remains the leading cause of death worldwide. Among many potential targets for pharmacological intervention, a promising strategy involves epoxyeicosatrienoic acid (EET) and soluble epoxide hydroxylase (sEH) inhibitio...
Is Leucine Restriction/Deprivation an Inducer of Adipose Browning? A Response to Jens Lund [0.03%]
亮氨酸限制/剥夺是诱导棕色脂肪生成吗？对Jens Lund的回应
Yehui Duan,Fengna Li,Yulong Yin
Yehui Duan
Progressive MS Alliance Industry Forum: Maximizing Collective Impact To Enable Drug Development [0.03%]
渐进性多发性硬化联盟行业论坛：最大化集体影响力以促进药物开发
P Zaratin,G Comi,T Coetzee et al.
P Zaratin et al.
The Progressive MS Alliance Industry Forum describes a new approach to address barriers to developing treatments for progressive multiple sclerosis (MS). This innovative model promises to facilitate robust collaboration between industry, ac...
Taku Nagai,Junichiro Yoshimoto,Takayuki Kannon et al.
Taku Nagai et al.
Dopamine signaling in the brain is a complex phenomenon that strongly contributes to emotional behaviors. Medium spiny neurons (MSNs) play a major role in dopamine signaling through dopamine D1 receptors (D1Rs) or dopamine D2 receptors (D2R...